

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

February 2010

Volume 13, Number 2

For health professionals who care for cancer patients
Available online at www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate

INSIDE THIS ISSUE

- [Editor's Choice: Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts](#) – Gastrointestinal: Carcinoma of the Anal Canal; Leukemia/Bone Marrow Transplant: Bloodwork Frequency for [Imatinib](#), [Nilotinib](#), [Dasatinib](#)
- [Cancer Drug Manual](#) – **New:** Azacitidine **Revised:** Cetuximab, Fluorouracil, Lanreotide, Nilotinib
- [Benefit Drug List](#) – Capecitabine, Trastuzumab
- [List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts](#): **New:** GICART, GICPART, GIFUPART, UGIGAVCCT, UGIGAVCFT, GIGAVTR, LKCMLI, ULKCMLN, LUSCPERT **Revised:** BRAVTR, UGIAJFFOX, UGIAVCETIR, UGICAPOX, UGICOXB, UGIFFOXB, UGIFOLFOX, GIFUART, UGIRAJFFOX, GUBEP, LKCMLI, ULKCMLD, ULKCMLN, LYIVACR, ULYRMTN, UMYBORTEZ, UMYLENDEX, SAAI, SAAVI, SAIME, SAVACM
- [Website Resources and Contact Information](#)

EDITOR'S CHOICE:

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

The **Gastrointestinal Tumour Group** has introduced several chemoradiation protocols as curative treatment options for carcinoma of the anal canal with capecitabine replacing infusional fluorouracil (GICART, GICPART) and with cisplatin as an alternative to mitomycin (GIFUPART). The Tumour Group has also revised all oxaliplatin-based protocols with guidance on the diluent volume to be used when smaller doses of oxaliplatin are prescribed.

The **Leukemia/Bone Marrow Transplant Group** has clarified the frequency of bloodwork to be done during the initial therapy for imatinib, nilotinib and dasatinib.

CANCER DRUG MANUAL

Azacitidine Interim Monograph has been developed. This is a new cytotoxic agent used for higher-risk myelodysplastic syndrome (MDS). The recommended dose is 75 mg/m² given subcutaneously for 7 consecutive days, repeated every 28 days on a 28-day cycle. The BC Cancer Agency Provincial Systemic Therapy Program is not currently funding azacitidine (see details in the January 2010 issue www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate).

Cetuximab Monograph has been updated to include a new dosing regimen and administration guidelines (500 mg/m² every 2 weeks) which is the BCCA standard when given with irinotecan for metastatic colorectal cancer (UGICETIR protocol). This more convenient regimen has been shown to be similar to the weekly dosing regimen in pharmacokinetic results and clinical response rates.

Fluorouracil Monograph has been revised to include potential interaction with phenytoin (see details in the September 2009 issue www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate). Additional pharmacokinetic information has been included in the **Lanreotide Monograph** to describe dose-dependent plasma concentrations and clearance data. The **Nilotinib Patient Handout** has been revised to use similar wording for abnormal heart rhythm as in the lapatinib patient handout.

BENEFIT DRUG LIST

The following programs have been added on the benefit list as class II indications effective 1 February 2010:

- **Capecitabine**
 - in combination with mitomycin and radiation therapy as curative combined modality therapy for carcinoma of the anal canal (GICART)
 - in combination with cisplatin and radiation therapy as curative combined modality therapy for carcinoma of the anal canal (GICPART)
- **Trastuzumab**
 - continuation of palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using trastuzumab (GIGAVTR)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New and revised protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indication Request) approval are prefixed with the letter **U**.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GICART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy
GICPART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Cisplatin, Capecitabine and Radiation Therapy
GIFUPART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Cisplatin, Infusional Fluorouracil and Radiation Therapy
UGIGAVCCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Using Cisplatin, Capecitabine and Trastuzumab
UGIGAVCFT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Using Cisplatin, Infusional Fluorouracil and Trastuzumab

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIGAVTR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Continuation of Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Using Trastuzumab
LKCMLI	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Therapy for Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Imatinib
ULKCMLN	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Nilotinib
LUSCPERT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) Using Cisplatin, Etoposide and Radiation

REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVTR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return appointment section clarified</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab
UGIAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dilution volume of oxaliplatin clarified, Eligibility and Title revised</i>	Adjuvant Combination Chemotherapy for Stage III Colon Cancer Using Oxaliplatin, 5-Fluorouracil and Folinic Acid (Leucovorin)
UGIAVCETIR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>References updated</i>	Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan
UGICAPOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dilution volume of oxaliplatin clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, and Capecitabine
UGICOXB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dilution volume of oxaliplatin clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
UGIFFOXB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dilution volume of oxaliplatin clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, 5-Fluorouracil, Folinic Acid (Leucovorin) and Bevacizumab
UGIFOLFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dilution volume of oxaliplatin clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, 5-Fluorouracil and Folinic Acid (Leucovorin)
GIFUART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and treatment sections revised, reference added</i>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Infusional Fluorouracil and Radiation Therapy
UGIRAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dilution volume of oxaliplatin clarified</i>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, 5-Fluorouracil and Folinic Acid (Leucovorin)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GUBEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment title modified, hydration added, electrolytes clarified under Tests, filgrastim indications added</i>	Curative Therapy for germ cell cancer using with Bleomycin, Etoposide, Cisplatin for Germ Cell Cancers
LKCMLI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests sections and dispensing quantity clarified</i>	Therapy for Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Imatinib
ULKCMLD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Test sections clarified; interaction section clarified in handout</i>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Dasatinib
ULKCMLN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests sections clarified</i>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Nilotinib
LYIVACR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Precaution for Ifosfamide CNS toxicity added</i>	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab
ULYRMTN	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Booking appointment section clarified</i>	Maintenance Rituximab for Indolent Lymphoma
UMYBORTEZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dosing for hepatic impairment revised</i>	Treatment of Multiple Myeloma using Bortezomib with Dexamethasone
UMYLENDEX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Minor typos corrected</i>	Treatment of Multiple Myeloma Using Lenalidomide (REVLIMID®) and Dexamethasone
SAAI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Test clarified, furosemide added Treatment section for diuresis</i>	Doxorubicin – Ifosfamide - Mesna For Use In Patients With Advanced Soft Tissue Sarcoma
SAAVI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Test clarified, furosemide added to Treatment section for diuresis</i>	Ifosfamide for Use in Patients with Advanced Soft Tissue Sarcoma
SAIME	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Premedications clarified</i>	Etoposide, Ifosfamide-Mesna for Patients with Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumor (PNET) or Rhabdomyosarcoma or Advanced Soft Tissue or Bony Sarcomas
SAVACM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests and premedications clarified</i>	Adjuvant Therapy for Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumour (PNET) or Rhabdomyosarcoma With Pelvic Primaries or Chemotherapy Induced Hematuria Using Vincristine, Doxorubicin, Cyclophosphamide and Mesna

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
REIMBURSEMENT AND FORMS: BENEFIT DRUG LIST, CLASS II, BC CANCER AGENCY COMPASSIONATE ACCESS PROGRAM	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
CANCER DRUG MANUAL	www.bccancer.bc.ca/cdm
CANCER MANAGEMENT GUIDELINES	www.bccancer.bc.ca/CaMgmtGuidelines
CANCER CHEMOTHERAPY PROTOCOLS, PRE-PRINTED ORDERS, PROTOCOL PATIENT HANDOUTS	www.bccancer.bc.ca/ChemoProtocols
SYSTEMIC THERAPY PROGRAM POLICIES	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
SYSTEMIC THERAPY UPDATE	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate

CONTACT INFORMATION	www.bccancer.bc.ca	
BC CANCER AGENCY	(604) 877-6000	Toll-Free 1-(800) 663-3333
PROVINCIAL SYSTEMIC THERAPY PROGRAM	Ext 2247	mclin@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK BUSINESS AFFAIRS.....	Ext 2744	david.leung@bccancer.bc.ca
UPDATE EDITOR	Ext 2288	mdelemos@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK PHARMACY EDUCATORS...	www.bccancer.bc.ca/RS/CommunitiesOncologyNetwork/Educators/Pharmacists/cap_bcca@bccancer.bc.ca
COMPASSIONATE ACCESS PROGRAM OFFICE	Ext 6277	cap_bcca@bccancer.bc.ca
	Fax (604) 708-2026	
DRUG INFORMATION.....	Ext 6275	druginfo@bccancer.bc.ca
EDUCATION RESOURCE NURSE	Ext 2638	nursinged@bccancer.bc.ca
NURSING PROFESSIONAL PRACTICE	Ext 2623	ilundie@bccancer.bc.ca
LIBRARY/CANCER INFORMATION	1-(888)-675-8001.....	requests@bccancer.bc.ca
	Ext 8003	
OSCAR HELP DESK	1-(888)-355-0355.....	oscar@bccancer.bc.ca
	Fax (604) 708-2051	
PHARMACY CHEMOTHERAPY CERTIFICATION	(250) 712-3900	rxchemocert@bccancer.bc.ca
	Ext 686741	
PHARMACY PROFESSIONAL PRACTICE	(250) 519.5574	jkippen@bccancer.bc.ca
ABBOTSFORD CENTRE (AC)	(604) 851-4710	Toll-free: 1-(877) 547-3777
CENTRE FOR THE SOUTHERN INTERIOR (CCSI)	(250) 712-3900	Toll-Free 1-(888) 563-7773
FRASER VALLEY CENTRE (FVCC)	(604) 930-2098	Toll-Free 1-(800) 523-2885
VANCOUVER CENTRE (VCC).....	(604) 877-6000	Toll-Free 1-(800) 663-3333
VANCOUVER ISLAND CENTRE (VICC)	(250) 519-5500	Toll-Free 1-(800) 670-3322

Editorial Review Board

Mário de Lemos, PharmD, MSc (Oncol) (Editor)
 Caroline Lohrisch, MD
 Johanna Den Duyf, MA
 Poonam Kothare (Editorial clerk)

Judy Oliver, BScN, MEd
 Beth Morrison, MLS
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)